MARKET WIRECNBC • 2h ago
Here are 3 big things we're watching in the stock market in the week aheadThe market could use a few victories in the days ahead, which will be filled with more earnings, an election, and jobs data.
Why SXTP Stock surged +11.87% Today — RQD Quant Desk Flash
$0.95 +11.87% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $0.97
60 Degrees Pharmaceuticals Inc. (SXTP) carries a Roarable Rating of D (Sell) with 50/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D • SELL / AVOID
Cap $3.3M
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $0.97 (+1.95%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record: Scores of 50/100 (D) historically posted market-perform odds over rolling 90-day windows (-1.4% avg 90D alpha vs SPY • 49.3% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →RQD QUANT TACHOMETERSELL / AVOID • D
JEV AI Jury Split (Battleground)
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw D- · Rk C
Each axis scored 0–20
12M PRICE TARGET CONE-3.2% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for SXTP)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (50/100 Composite)
🔍 WHY SXTP SCORES 50/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+14/20 pts (28% of score)
20D Institutional Volume Accumulation (±12.5% realized swing band)
▲ #2 Bullish Driver: Macro Regime Fit+14/20 pts (28% of score)
FRED Regime × Technicals: 4% of 52W Range • RSI-14 at 48.6 (NEUTRAL RANGE)
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)
Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade C$0.96-10.4% Next Q
58
Q2 (-2Q)Grade C$0.86+1.2% Next Q
55
Q3 (-1Q)Grade C-$0.87+9.2% Next Q
53
CurrentGrade D$0.95-1.4% Hist 90D α
50
Trajectory: C (58) → D (50)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a SXTP Turnaround Squeeze
While SXTP currently carries a cautious 50/100 (D) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.01) and Max Pain ($1.00) forces dealer call-delta covering toward $9.05.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $SXTP• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “SXTP Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why SXTP Stock surged +11.87% Today — RQD Quant Desk Flash
60 Degrees Pharmaceuticals Inc. (SXTP) surged +11.87% to $0.95, trading at 4% of its 52-week range ($0.59 – $8.62). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 4% of its 52-week range ($0.59 – $8.62) with RSI-14 at 48.6 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $0.95 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D (Sell) backed by 22.3% gross margin and $0 annual free cash flow.
Live SXTP Headlines & Catalysts
MARKET WIRECNBC • 3h ago
Democratic Rep. Stevens endorses Rogers over El-Sayed in Michigan Senate electionHaley Stevens had lost the Democratic nomination for Senate in Michigan to Abdul El-Sayed earlier this year.
RISK WATCHReuters • 4h ago
Israeli strikes kill eight people in Gaza - medics say - ReutersIsraeli strikes kill eight people in Gaza - medics say Reuters
MARKET WIREReuters • 5h ago
Russia's FSB says minor detained over park attack threat after US tip-off - ReutersRussia's FSB says minor detained over park attack threat after US tip-off Reuters
MARKET WIREReuters • 6h ago
Iran, Qatari mediators hold third day of talks to end US-Iran war - ReutersIran, Qatari mediators hold third day of talks to end US-Iran war Reuters
CATALYSTReuters • 7h ago
Qatar surges, bucking Gulf market slide on Iran war concerns - ReutersQatar surges, bucking Gulf market slide on Iran war concerns Reuters
MARKET WIREReuters • 7h ago
OPEC+ keeps December oil output targets steady ahead of tougher call for 2027 - ReutersOPEC+ keeps December oil output targets steady ahead of tougher call for 2027 Reuters
MARKET WIREReuters • 7h ago
German ministers pledge tough action after rioters damage stores in Frankfurt - ReutersGerman ministers pledge tough action after rioters damage stores in Frankfurt Reuters
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring SXTP)
- ✓Walkthrough of SXTP's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
SXTP // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -39.87%▼ DESCENDING CHANNEL
2026-10-30O $0.94H $0.97L $0.90C $0.95VOL 73.2K
RES: $1.59SUP: $0.57SMA50: $1.01SMA200: $1.77
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
SXTP Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +65.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on SXTP today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for SXTP. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for SXTP today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (SXTP)
Health Care Rank #355 of 1016
⚔️ EOCN vs SXTP Full Matrix →
1. Head-to-Head Health Care Peer Comparison (SXTP vs. EOCN, CVKD, GRI, ERNA)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, 60 Degrees Pharmaceuticals Inc. (SXTP) ranks #355 by composite RQD confidence (50/100, grade D) and #976 by equity capitalization ($3.3M). Within this direct 5-issuer industry benchmark cohort, SXTP leads on earnings valuation at N/A trailing P/E, while SXTP leads on capital efficiency and profitability with -35.0% ROIC and 22.3% gross margin. SXTP currently leads its immediate peer cohort in composite quantitative strength at 50/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| SXTP
ACTIVE
60 Degrees Pharmaceuticals Inc. | D | 50/100 | — | 22.3% | -35.0% | +11.87% | $3.3M | Benchmark Subject |
| EOCN Eocene Ltd. | D | 47/100 | — | — | -35.0% | +0.62% | $3.4M | /eocn-vs-sxtp → |
| CVKD Cadrenal Therapeutics Inc. | D- | 40/100 | — | — | -35.0% | -0.47% | $3.4M | /cvkd-vs-sxtp → |
| GRI GRI Bio Inc. | D- | 38/100 | — | — | -35.0% | -3.38% | $3.4M | /gri-vs-sxtp → |
| ERNA Ernexa Therapeutics Inc. | D | 46/100 | — | — | -35.0% | +6.57% | $3.4M | /erna-vs-sxtp → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001946563In its most recent audited fiscal period (FY2025, filed 2025-12-31), 60 Degrees Pharmaceuticals Inc. (SXTP) reported GAAP revenue of $1.0M (+65.5% vs. FY2024 revenue of $607.6K , and +296.5% cumulative change since FY2023) , GAAP net income of -$7.4M, operating cash flow of -$6.8M, and free cash flow of -$7.0M (-21.5% YoY). On the balance sheet, SXTP closed FY2025 with $5.4M in total assets against $144.0K in total debt (Altman Z-Score: N/A, Piotroski F-Score: 5/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $1.0M | -$7.4M | -$6.8M | -$7.0M | $5.4M | $144.0K |
| FY2024 (FY) | 2024-12-31 | $607.6K | -$7.9M | -$5.6M | -$5.8M | $5.8M | $147.1K |
| FY2023 (FY) | 2023-12-31 | $253.6K | -$3.8M | -$4.5M | -$4.5M | — | — |
3. SXTP Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs SXTP stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-01, 60 Degrees Pharmaceuticals Inc. (NASDAQ: SXTP) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 50/100 at a spot price of $0.95 (+11.87% 1D, market cap $3.3M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 14/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 14/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, SXTP ranks #355 in composite RQD confidence.
How does SXTP compare to EOCN and CVKD in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), SXTP carries a Roarable D (50/100 RQD), trailing P/E of N/A, gross margin of 22.3%, and ROIC of -35.0%. By comparison, EOCN (Eocene Ltd.) holds a D grade (47/100 RQD, P/E N/A, ROIC -35.0%, cap $3.4M) and CVKD (Cadrenal Therapeutics Inc.) posts a D- grade (40/100 RQD, P/E N/A, ROIC -35.0%, cap $3.4M). Among the 5-stock peer group, SXTP leads on earnings multiple (N/A) while SXTP leads on capital efficiency (-35.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for SXTP?
Per SXTP's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001946563), 60 Degrees Pharmaceuticals Inc. generated $1.0M in revenue (+65.5% YoY), -$7.4M in net income, and -$7.0M in free cash flow against $5.4M in total assets and $144.0K in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is SXTP trading relative to its 50-day, 200-day, and 52-week technical levels?
SXTP last traded at $0.95 (+11.87% on volume of 358,283 shares), positioning the stock -5.94% below its 50-day simple moving average ($1.01) and -46.33% below its 200-day simple moving average ($1.77). Across its 52-week range of $0.59 to $8.62, SXTP sits at the 4.5% percentile with a 14-day RSI of 48.6 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $1.07).
SXTP Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is SXTP stock moving today?
Why SXTP Stock surged +11.87% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.